Cocrystal Pharma
Business Services · Washington, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
19805 N Creek Pkwy, Bothell, Washington,...Phone Number
(877) 262-7123Website
www.cocrystalpharma.comRevenue
-Stock Symbol
COCPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for theRead more
Cocrystal Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cocrystal Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cocrystal Pharma launches new products
Click to see if Cocrystal Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on Cocrystal Pharma recently announced quarterly report
Check out if Cocrystal Pharma is spiking on competitors!
Cocrystal Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Cocrystal Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cocrystal Pharma has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cocrystal Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Cocrystal Pharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cocrystal Pharma
Compare insights from companies similar to Cocrystal Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cocrystal Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cocrystal Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cocrystal Pharma.
Cocrystal Pharma Tech Stack
A closer look at the technologies used by Cocrystal Pharma
Most Recent Scoops
Project
Cocrystal Pharma has announced a full pipeline including multiple influenza assets, a norovirus and COVID-19 drug (CDI-988) that has completed Phase 1, and additional respiratory disease candidates.
Product Development, Medical Research, Pharmaceuticals
Project
Cocrystal Pharma has selected norovirus as the initial indication for CDI-988 due to the lack of existing treatments, large market potential, and opportunities for stockpiling. The drug is being developed as both a therapeutic and preventive measure due to the rapid spread of norovirus in confined spaces.
Product Development, Medical Research, Pharmaceuticals
Earnings
reported a financial position of $4.8 million as of June 30, 2023, and recently raised an additional $4.7 million with $8.3 million potential from warrants.
Earnings, Business Finance, Finance
Project
Cocrystal Pharma is pursuing a human challenge study for norovirus as the most efficient way to control infection, test both treatment and prevention, and gather data quickly. The company's confidence in its approach is based on its unique crystallization platform and positive preclinical and Phase 1 results.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Cocrystal Pharma News & Media
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
BOTHELL, Wash., May 26, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its novel direct-acting antivirals demonstrate pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes hantavirus, which is essential for viral replication and transcription. In vitro potency data showCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three months ended March 31, 2026.Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled “First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel MechWe're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cocrystal Pharma
Sign Up For FreeTo access detailed company insights
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infectio... Read More
